NPI registry status
Active
2026 NPPES data Hematology & Oncology Physician NPI 1427022656 M.D.
Verify on CMS → Amer Rafiaa, M.D.
Hematology & Oncology Physician in Brooklyn, New York.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 11,232 in Hematology & Oncology Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Federal data, no proprietary rating.
We show these CMS records as-is - no composite score, no star rating, no editorial opinion layered on top.
Prescribing volume
7K
Medicare Part D claims · 325 beneficiaries · Hematology & Oncology Physician avg: 847
Generic prescribing
76%
generic claims · 23% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
67.8/100
▼ 16 pts below national avg 83.5 · Mid-tier
Industry payments
$303.88
12 payments · CMS Open Payments (Sunshine Act)
Source: CMS Medicare Part D Prescriber Public Use File, 2023
What the federal data shows
Amer Rafiaa, M.D. reported a CMS MIPS final score of 67.8/100 - below the 83.5 national average - and filed 7,104 Medicare Part D claims in 2023.
- 67.8/100
- MIPS score · -16 vs avg
- 7K
- Part D claims, 2023
- 76%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Amer Rafiaa, M.D.'s MIPS score vs every measured U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023, the federal quality measure. Clinicians whose score CMS assigned without scoring any category are excluded.
68 ≥ 8th percentile 8% of 454,083 measured providers are in lower value bands
Each bar is a band; taller bars hold more measured providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
The percentile is a conservative whole-score-point band: it counts only measured clinicians in lower score bands. A CMS MIPS metric is not a recommendation or a clinical-quality rating by PlainDoctor. See methodology § corpus placement.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
Where Amer Rafiaa, M.D. sits
This provider among hematology & oncology physician peers
Across the 4,019 hematology & oncology physician providers who report both Medicare Part D prescribing and a MIPS quality score, Amer Rafiaa, M.D. writes more Part D claims than 100% of them and scores higher on MIPS quality than 5% - placing this provider in the high-volume, lower-quality quadrant. Volume reflects patient-panel size and specialty, not quality; the two axes are independent.
Each dot is one hematology & oncology physician peer from a representative sample of 60; the gold marker is Amer Rafiaa, M.D.. Source: CMS Medicare Part D Prescriber data and the CMS Merit-based Incentive Payment System, 2023.
✓
Board certification likely (heuristic, not verified)
Amer Rafiaa, M.D. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting - signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Amer Rafiaa, M.D.?
Below national averagePrimary specialty
Hematology & Oncology Physician
Medicare Part D claims
7,104 8× vs specialty avg
MIPS final score
67.8/100 15.7 pts vs avg
Specialty distribution in New York
How Hematology & Oncology Physician compares to other specialties among New York providers
Medicare quality performance, MIPS
Amer Rafiaa, M.D.'s 2023 MIPS final score plotted against the Hematology & Oncology Physician national average
- MIPS Final Score
- 67.8/100
- vs 83.5 national avg · 2023 performance year
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Amer Rafiaa, M.D. appears in the CMS NPPES registry as a Hematology & Oncology Physician provider holding M.D. credentials at 445 BAY RIDGE PKWY, Brooklyn, NY, 11209, with a listed phone of (718) 333-5118. NPI 1427022656 was issued on 02/14/2006.
Medicare Part D records for calendar year 2023 show 7,104 prescription claims written by this provider, covering 325 Medicare beneficiaries and totaling roughly $2.7 million in drug spend, split 23% brand-name and 76% generic by claim count, with an opioid prescribing rate of 1.1%. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 67.8/100 for the 2023 performance year (Quality 94.1, Cost 67.2), compared with the 83.5 average among clinicians with a measured score.
Hematology & Oncology Physician is a mid-sized specialty nationwide, with 11,232 enrolled providers across 54 states and an average of 847 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline.
Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist, always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1427022656 |
|---|---|
| Specialty | Hematology & Oncology Physician |
| Credentials | M.D. |
| Gender | Male |
| NPI Issued | 02/14/2006 |
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
67.8106
Final Score
Measured-score avg: 83.5
94.1497
Quality
67.169
Cost
Reporting: Individual
Industry payments received (2024) - CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for Amer Rafiaa, M.D.. Source: openpaymentsdata.cms.gov.
Total received
$304
Largest payer
Celgene Corporation
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias, they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
License & disciplinary context - New York NYSBPMC 2023 annual report
Aggregate state board data only, NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~100K New York medical licensees in 2023 - they are NOT specific to Amer Rafiaa, M.D.. To verify Amer Rafiaa, M.D.'s current license status, search the NYSBPMC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
312
Total board actions, New York 2023
Across 302 cases
3.12
Actions per 1,000 licensees
New York statewide rate
probation
Most common action type
89 cases
NYSBPMC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the New York disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Typical
Amer Rafiaa, M.D. - brand share 23.0%
Hematology & Oncology Physician average
23% brand-name claims vs 76% generic, on 7,104 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
7,104
Total Claims
$2.7M
Total Drug Cost
325
Medicare Beneficiaries
Prescribing Breakdown
- 30-Day Fills
- 7,828
- Total Day Supply
- 188,928
- Brand vs Generic
- 23% brand / 76% generic
- Brand Drug Cost
- $2.2M
- Generic Drug Cost
- $450K
- Opioid Claims
- 75 (1.1% rate)
- Antibiotic Claims
- 141
Patient Demographics
- Average Patient Age
- 78.9 years
- Avg HCC Risk Score
- 2.92
- Gender Split
- 59% female / 41% male
- Age Distribution
- <65: 23, 65-74: 88, 75-84: 101, 85+: 113
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What Amer Rafiaa, M.D. prescribes most
Top Medicare Part D drugs by claim count, 2023
- Atorvastatin Calcium
Atorvastatin Calcium
357 claims
- Eliquis
Eliquis
343 claims
- Amlodipine Besylate
Amlodipine Besylate
340 claims
- Metformin Hcl
Metformin Hcl
205 claims
- Januvia
Januvia
196 claims
- Tamsulosin Hcl
Tamsulosin Hcl
180 claims
- Levothyroxine Sodium
Levothyroxine Sodium
143 claims
- Gabapentin 142
Gabapentin
142 claims
| Drug | Claims |
|---|---|
| Atorvastatin Calcium | 357 |
| Eliquis Apixaban | 343 |
| Amlodipine Besylate | 340 |
| Metformin Hcl | 205 |
| Januvia Sitagliptin Phosphate | 196 |
| Tamsulosin Hcl | 180 |
| Levothyroxine Sodium | 143 |
| Gabapentin | 142 |
| Metoprolol Succinate | 139 |
| Simvastatin | 115 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Hematology & Oncology Physician Overview
How Amer Rafiaa, M.D. fits within the Hematology & Oncology Physician landscape nationally.
11,232
Hematology & Oncology Physician Providers in US
54
States with Hematology & Oncology Physician
847
Avg Claims per Provider
Amer Rafiaa, M.D.'s 7,104 claims are above the specialty average of 847.
Nearby Hematology & Oncology Physician Providers in New York
Other clinicians with the same primary specialty enrolled in New York, drawn from the same CMS NPPES roster as Rafiaa.
Dr. Anum Aamir
M.D
Astoria, NY
Dr. Robert Abderhalden
MD
Painted Post, NY
Dr. Mohammad Maher Abdul Hay
MD
New York, NY
Dr. George Abraham
MD
Rochester, NY
Dr. Avram Abramowitz
M.D.
Fresh Meadows, NY
Compare Hematology & Oncology Physician nationally: see state-by-state distribution →
Before you book an appointment
Use this federal record as your verification checklist, not as a recommendation.
- Confirm the NPI record is current in the official CMS registry, providers update their own NPPES details, and moves can lag. Verify this NPI
- Check the active license and any disciplinary history with the New York medical board, federal registration is not a license check. Credential verification guide
- Weigh a second option: compare this provider with a nearby Hematology & Oncology Physician peer on Medicare volume and prescribing patterns. Compare providers
Medicare Part D and MIPS figures describe practice patterns in federal programs only, they are not quality ratings, and PlainDoctor does not rate, rank, or recommend providers.
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
How to Find a Doctor
Step-by-step guide to choosing a provider
Verify Credentials
Check NPI, board certification & license status
Medical Specialties Explained
Who treats what and how specialties differ
Understanding Medicare Claims Data
What prescribing data reveals about a provider
In-Network vs Out-of-Network
How insurance networks affect your costs
Telehealth Guide
Virtual care options and coverage in 2026
Explore New York
Frequently Asked Questions
What is Amer Rafiaa, M.D.'s specialty? ▼
Amer Rafiaa, M.D. specializes in Hematology & Oncology Physician and practices in Brooklyn, New York. Credentials: M.D..
How much does Amer Rafiaa, M.D. prescribe under Medicare Part D? ▼
In 2023, Amer Rafiaa, M.D. wrote 7,104 Medicare Part D claims totaling $2.7M in drug costs for 325 beneficiaries.
What is Amer Rafiaa, M.D.'s Medicare quality score? ▼
Amer Rafiaa, M.D. has a CMS MIPS Final Score of 67.8/100 (Quality: 94.1, Cost: 67.2). The average MIPS Final Score across the 454,083 clinicians with at least one published category score is 83.5; clinicians whose score CMS assigned without scoring any category are excluded from that average. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is Amer Rafiaa, M.D. located? ▼
Amer Rafiaa, M.D. is located at 445 BAY RIDGE PKWY, Brooklyn, NY, 11209. Phone: (718) 333-5118.
What is Amer Rafiaa, M.D.'s NPI number? ▼
Amer Rafiaa, M.D.'s National Provider Identifier (NPI) is 1427022656, issued on 02/14/2006.
Does Amer Rafiaa, M.D. prescribe more brand-name or generic drugs? ▼
Amer Rafiaa, M.D.'s prescribing is 23% brand-name and 76% generic drugs by claim count, with $2.2M in brand drug costs.
Does Amer Rafiaa, M.D. prescribe opioids? ▼
Yes, Amer Rafiaa, M.D. had 75 opioid claims in 2023 with an opioid prescribing rate of 1.1%.
How many Hematology & Oncology Physician providers are there in the US? ▼
There are 11,232 Hematology & Oncology Physician providers across 54 states in the US. The average Hematology & Oncology Physician provider writes 847 Medicare Part D claims per year.
What drugs does Amer Rafiaa, M.D. prescribe most often? ▼
Based on 2023 Medicare Part D data, Amer Rafiaa, M.D.'s most frequently prescribed drugs include Atorvastatin Calcium, Eliquis, Amlodipine Besylate. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does Amer Rafiaa, M.D. accept Medicare? ▼
Amer Rafiaa, M.D. appears in CMS Medicare data with 7,104 Part D claims and 325 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify Amer Rafiaa, M.D.'s credentials? ▼
Amer Rafiaa, M.D.'s NPI is 1427022656 with credentials M.D.. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) - 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology
Every figure on PlainDoctor is rendered directly from the federal CMS NPPES registry, Medicare Part D, MIPS, and Open Payments records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.